Free Trial

Entera Bio (ENTX) Competitors

Entera Bio logo
$2.04 0.00 (0.00%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$2.04 0.00 (-0.25%)
As of 07/17/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENTX vs. RCKT, OCGN, GLUE, HRTX, CADL, AVIR, NGNE, TNXP, PVLA, and ABEO

Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Rocket Pharmaceuticals (RCKT), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), Heron Therapeutics (HRTX), Candel Therapeutics (CADL), Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Tonix Pharmaceuticals (TNXP), Palvella Therapeutics (PVLA), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry.

Entera Bio vs. Its Competitors

Entera Bio (NASDAQ:ENTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Entera Bio has higher revenue and earnings than Rocket Pharmaceuticals. Entera Bio is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entera Bio$180K515.10-$9.54M-$0.26-7.85
Rocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.27

In the previous week, Rocket Pharmaceuticals had 45 more articles in the media than Entera Bio. MarketBeat recorded 45 mentions for Rocket Pharmaceuticals and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Rocket Pharmaceuticals' score of 0.17 indicating that Entera Bio is being referred to more favorably in the media.

Company Overall Sentiment
Entera Bio Very Positive
Rocket Pharmaceuticals Neutral

Entera Bio has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Rocket Pharmaceuticals' return on equity of -64.92% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Entera Bio-4,525.11% -95.10% -82.77%
Rocket Pharmaceuticals N/A -64.92%-56.13%

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 10.4% of Entera Bio shares are held by insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Entera Bio presently has a consensus price target of $10.00, suggesting a potential upside of 390.20%. Rocket Pharmaceuticals has a consensus price target of $18.60, suggesting a potential upside of 456.89%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Entera Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Rocket Pharmaceuticals
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.41

Summary

Rocket Pharmaceuticals beats Entera Bio on 9 of the 15 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTX vs. The Competition

MetricEntera BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$92.72M$2.94B$5.57B$9.34B
Dividend YieldN/A2.45%3.80%4.06%
P/E Ratio-7.8520.2928.1019.86
Price / Sales515.10302.32441.4199.96
Price / CashN/A43.1635.8457.94
Price / Book8.877.838.265.67
Net Income-$9.54M-$55.11M$3.24B$257.80M
7 Day Performance17.92%3.21%1.48%1.87%
1 Month Performance2.51%12.86%8.07%10.92%
1 Year Performance9.09%5.06%30.29%18.51%

Entera Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTX
Entera Bio
2.9359 of 5 stars
$2.04
flat
$10.00
+390.2%
+7.9%$92.72M$180K-7.8520Positive News
RCKT
Rocket Pharmaceuticals
4.8488 of 5 stars
$3.05
+3.0%
$18.60
+509.8%
-85.8%$325.71MN/A-1.16240Trending News
Gap Up
OCGN
Ocugen
1.3955 of 5 stars
$1.11
-2.6%
$6.00
+440.5%
-45.4%$324.15M$4.05M-5.8480News Coverage
GLUE
Monte Rosa Therapeutics
2.1256 of 5 stars
$5.26
+1.9%
$15.33
+191.5%
+24.5%$323.54M$159.49M65.7690News Coverage
Positive News
HRTX
Heron Therapeutics
3.5657 of 5 stars
$2.12
-2.8%
$5.00
+135.8%
-42.9%$323.44M$148.52M-35.33300
CADL
Candel Therapeutics
2.5172 of 5 stars
$6.43
+10.7%
$22.00
+242.1%
+5.3%$322.16MN/A-4.8060Positive News
AVIR
Atea Pharmaceuticals
2.7633 of 5 stars
$3.76
+2.5%
$6.00
+59.6%
-10.6%$321.78MN/A-2.2870Positive News
NGNE
Neurogene
3.4539 of 5 stars
$22.26
+3.9%
$46.17
+107.4%
-49.0%$317.47M$925K-5.1290Positive News
TNXP
Tonix Pharmaceuticals
2.5416 of 5 stars
$42.78
+4.7%
$585.00
+1,267.5%
-20.8%$314.73M$10.04M-0.0250Gap Up
PVLA
Palvella Therapeutics
2.5393 of 5 stars
$27.55
+4.1%
$46.29
+68.0%
N/A$304.59MN/A-2.28N/APositive News
ABEO
Abeona Therapeutics
3.7509 of 5 stars
$5.92
+3.1%
$19.25
+225.2%
+22.3%$302.87M$3.50M-4.6690

Related Companies and Tools


This page (NASDAQ:ENTX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners